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three specific forms of LD: Epstein-Barr-Virus-related post-transplant like LD, hepato-splenic
T-cell lymphoma and post-mononucleosis lymphoproliferation. The risk of the two latter forms
of LD can be reduced when considering specific immunosuppressive strategies in young males. It
is still unclear whether the risk of uterine cervix abnormalities is increased in IBD women,
irrespective of the use of immunosuppressants. Given the excess risk demonstrated in various
other contexts of immunosuppression, it is currently recommended that all women with IBD,
particularly those receiving immunosuppressants, strictly adhere to a screening program of
cervical surveillance and undergo vaccination against HPV, when appropriate. Patients with IBD
receiving immunosuppressants are at increased risk of skin cancers. The risk of non-melanoma
skin cancer is notably increased in patients receiving thiopurines. Recent data suggest that the
risk of melanoma is mildly increased in patients exposed to anti-TNF therapy. All IBD patients
should adhere to a program of sun protection and dermatological surveillance, whose details
should take into account the other non-IBD-related risk factors.
© 2013 The Authors. Published by Elsevier B.V. on behalf of European Crohn's and Colitis
Organisation.Open access under CC BY-NC-ND license.Contents
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Inflammatory bowel disease (IBD)-related cancers are those
attributable to chronic tissue inflammation and/or todrug-induced immunosuppression. Extra-intestinal cancers
belong to the second category. We focus here on
lymphoproliferative disorders (LD), skin cancers and uterine
cervix abnormalities, because recent epidemiological
33ECCO workshop-Extra-intestinal cancersadvances in these fields have significant consequences in
clinical practice.
1.1. Lymphoproliferative disorders
LD in IBD have become a major concern for both patients and
physicians. The role of immunosuppressive therapy, as well
as the role of local and systemic inflammation, is inter-
linked, and thus difficult to distinguish. Although LD are
globally infrequent in young patients, their incidence can be
relatively high in some specific subpopulations and their
outcomes are often severe and sometimes rapidly fatal.
Here we review available data on LD pathogenesis, risk
factors and epidemiology.
1.2. Epidemiology and Risk Factors
The incidence of LD has increased markedly worldwide since
the 1970s1 and particularly in western countries.2 The
current lifelong risk for a male reached approximately 2%.
Although case series and hospital-based studies suggested an
increased risk of LD in IBD patients, population-based studies
showed no increase or very little increase risk of LD in
IBD.3–6 However, the risk of LD has been shown to be
increased by some immunosuppressants and in some specific
subpopulations of IBD patients.
1.2.1. General Risk Factors for LD
Immunosuppression is one of the well established risk
factor for LD. Most of the immunodeficiency-associated LD
are of diffuse large B cells type and often arise in
extra-nodal sites such as brain or gastrointestinal tract.
Defective immune surveillance of Epstein-Barr virus (EBV) is
often involved in the lymhomagenesis process in this
setting.7 In the post-transplant setting, EBV viral load is a
good marker of the risk of LD,8 but this strategy has not been
evaluated in IBD, because it would require very large cohort
studies given the relatively low incidence of LD in this
population.
The other general risk factors of LD have been less
studied. The incidence of LD increases with age and is
slightly higher in men 9. Genetic factors are also involved
because familial clusters have been described. In addition to
EBV, other specific infectious agents have also been
involved, such as human herpes virus 8 (HHV-8), human T
lymphotropic virus 1 (HTLV-1), Helicobacter pylori and
hepatitis C virus (HCV).
1.2.2. Specific Risk Factors for LD in IBD
1.2.2.1. Role of Local Inflammation and Immune
Activation. Inflammation and immune activation them-
selves are considered to be involved in lymphomagenesis in
inflammatory and autoimmune setting, and might play a role
in LD onset in IBD. In autoimmune diseases, such as lupus
erythematosus, Hashimoto thyroiditis and Sjögren's syn-
drome, the risk of LD is increased 3-to 18-fold and seems to
correlate with disease severity. Moreover, LD are often
located in the organ in which occurs the auto-immune
reaction.10 In inflammatory diseases such as rheumatoid
arthritis, there is an increased risk of LD (approximately2-fold) which seems to correlate with disease activity,
independently of the treatment.11 In chronic suppuration
such as long-standing pyothorax, characterized by pure
inflammation without auto-immunity, there is an increased
risk of pleural LD with a major role of EBV infection.12 Only
few data are available in IBD, but it has been shown recently
that those patients have an excess risk of primary intestinal
LD.13 In this context, LD arise in IBD lesions and are often
EBV-associated 13. Moreover, it has also been shown in the
CESAME study that the duration of the disease is an
independent risk factor for LD.3 These results suggest a
role of local inflammation (and possibly of EBV) in IBD-
associated lymphomagenesis.
1.2.2.2. Immunosuppressants. Immunosuppressants are
the other major factor of lymphomagenesis in IBD. Of note,
it is difficult to distinguish between the role of autoimmu-
nity/inflammation and that of immunosuppressants in IBD
patients, as these treatments are usually prescribed to
patients with severe disease.
1.2.2.2.1. Thiopurine-associated LD. Thiopurines have
been particularly implicated in IBD-associated LD risk.
Besides immunosupression itself, thiopurines might have
specific pro-carcinogenic effects. It has notably been
suggested that azathioprine promotes clonal expansion of
rare mismatch repair (MMR)-defective myeloid cells, thus
possibly playing a role in the development of some haema-
tological malignancies.14 Meta-analysis of cohort studies and
nationwide studies has shown that patients with IBD exposed
to thiopurines have a three- to fivefold increased risk of
developing LD.3,15
Three subtypes of thiopurine-associated LD must be
considered (Table 1).
1.2.2.2.1.1. LD due to Proliferation of Chronically EBV-
infected Lymphocytes. Most of the cases of LD observed in
IBD patients treated with thiopurine are associated with
EBV.3,16 This suggests that, similarly to post-transplantation
setting, immunosuppression plays a major role in lympho-
magenesis through a defect in EBV immuno-surveillance (see
paragraph on immunosuppression as one of the general risk
factors for LD).
1.2.2.2.1.2. Post-mononucleosis Lymphoprolifera-
tions. Recently, concerns were expressed regarding the
risk of early postmononucleosis lymphoproliferation associ-
ated or not with haemophagocytic lymphohystiocytosis
(HLH) in thiopurine-treated IBD patients. Two fatal cases in
the CESAME cohort and one other fatal case have been
reported in young males,3,17 but the frequency of this
dramatic complication is possibly underreported and under-
estimated. Although the overall risk of early postmono-
nucleosis lymphoproliferation is very low in the total IBD
population, the crude risk in young (b 35 years) male
seronegative for EBV and exposed to thiopurines is high
(Table 1). It seems thus reasonable to consider avoiding
thiopurine in this subset of patient and preferring anti-TNF
monotherapy, because this complication has not been
reported yet in patients treated with anti-TNF alone.
1.2.2.2.1.3. HepatosplenicTCell Lymphoma. Hepatosplenic
T cell lymphoma (HSTCL) is an infrequent non-EBV-related
LD with about 200 cases reported in the literature, but it is
often rapidly fatal.18,19 Less than forty cases have been
reported in IBD to date. Patients were all treated by
Table 1 Azathioprine-related lymphoproliferative disorders.
Crude risk in
patients exposed
to thiopurines
per 1000
patient-years ⁎
Recommended To be discussed
in the near future
To be investigated
Post-transplant-like
lymphoma with
EBV reactivation
0.60 EBV viral load in case of
unusual symptoms$,
unexplained biological
inflammatory syndrome,
with or without increase
in the blood level of LDH
and beta2-microglobulin
and HLH
Monitoring EBV viral load
or T cells cytotoxic
functions
Early Postmononucleosis
lymphoproliferation in
EBV-seronegative young
(b35 years) male#
2.90 Avoiding thiopurines
in EBV-seronegative
young (b35 years)
male
- Identify involved genes
and mutations
- Genetic testing before
treatment
Hepatosplenic T cell
lymphoma in young
(b35 years) male
treated with thiopurine
alone or in association
with anti-TNFa
0.06 Avoiding association of
anti-TNFa and thiopurine
treatment beyond two
years in young (b35 years)
male
⁎ Data from the CESAME study ; # in the absence of EBV serological test for most patients in the CESAME study, the prevalence of EBV-
seronegative young male was estimated to be 20% ; $ unexplained headache, fatigue or fever, acquired adenopahies not attributable to
intestinal inflammation, increase size of the spleen or the liver.
34 F. Magro et al.thiopurines either alone or in association with anti-TNF
therapy (more that 50% of cases). Median duration of
thiopurine exposure in these patients is around 6 years
(only one patient received thiopurines for less than two
years). When data are available, patients are in most cases
males (N90% of the cases) with a young age (b35 years in
N90% of the cases). No case of HSTCL in IBD patient treated
by anti-TNF therapy alone (without thiopurines) has been
reported up to now, but one case that occurred in a patient
with rheumatoid arthritis receiving anti-TNF monotherapy
has been recently published 18. The role of anti-TNF therapy
in HSTCL pathogenesis is thus unclear in IBD, but anti-TNF
therapy might increase the risk of HSTCL in thiopurine-
treated patients. 19. Although the overall risk of HSTCL is
very low in IBD, it is probably clinically relevant in young
(b35 years) men treated with combotherapy with more
than 2 years of thiopurine intake.
1.2.2.2.2. Methotrexate, Anti-TNF therapy, and Risk of
LD. The impact of methotrexate on lymphomagenesis has
been poorly studied in IBD and can be extrapolated only from
studies performed in other inflammatory conditions and
particularly in rheumatoid arthritis. In the context of
rheumatologic diseases, the role of methotrexate on the
risk of LD is controversial. Several cases of LD have been
reported in methotrexate-treated patients with RA,20 but a
French nationwide study showed that the risk of non-
Hodgkin lymphoma was not significantly increased in
patients receiving methotrexate.21. Although no similar
studies are available (or will be available in the near future)
in IBD, the risk of LD associated with methotrexate seems to
be low in IBD.
The risk of LD associatedwith anti-TNF therapy is difficult to
assess in IBD because most patients receiving these biologics
are also treated, or have been treated, with thiopurines ormethotrexate. In a systematic review of registries and
prospective observational studies of patients with rheumatoid
arthritis, the pooled estimate for the risk of LD in patients
exposed to anti-TNF therapy was not significantly increased.22
Analysis of the five-year follow-up of the Crohn’s Therapy,
Resource, Evaluation, and Assessment Tool (TREAT) registry,
showed a similar overall incidence of LD in infliximab-treated
patients (0.05 per 100 patient-years) and those who received
other treatments only (0.06 per 100 patient-years).23 Although
these results seem reassuring, a large safety cohort is urgently
needed to compare the risk of neoplasia and infections
associated with monotherapy and combotherapy, with an
adjustment for IBD activity.1.3. Clinical Presentation and Diagnosis (Including
Imaging Techniques if Necessary)
Clinical presentation and diagnosis do not differ from cases
of LD in patients without IBD.1.4. Early Diagnosis or Detection/Surveillance
There is no specific method for early diagnosis of LD. In IBD
patients receiving thiopurines, LD should be suspected in
case of unexplained headache, fatigue or fever, acquired
adenopathy not attributable to intestinal inflammation,
increase size of spleen or liver, unexplained biological
inflammatory syndrome, with or without increase in the
blood level of LDH and beta2-microglobulin and HLH. In
these situations, routine workout should be performed, EBV
viral load should be assessed and hematologist opinion
should be requested.
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Theoretically, EBV-induced thiopurine-associated LD could be
prevented if immunosuppressants are withdrawn before the
occurrence of LD. Unfortunately, there is no defined method
to identify this “prelymphoma” state. In the post-transplant
setting, the risk of LD is particularly high in the first year after
transplantation, notably in EBV-seronegative recipients.
Transplant specialists have developed strategies, mainly
based on the monitoring of EBV viral load, to identify
prelymphoma state and initiate preemptive treatment.24
However, there is no consensus on this topic regarding the
method to use and the threshold for EBV viral load. Moreover,
this strategy is not validated in IBD as transient increase in
EBV viral load can be observed during IBD flare.25 The
appropriate monitoring of thiopurine-treated IBD patients
regarding EBV-induced LD is thus not defined and would
benefit from specific investigations.
Based on the epidemiology of HSTCL in IBD, it seems
reasonable to consider avoiding association of anti-TNF
therapy and thiopurine treatment beyond two years in young
(b35 years) men. Regarding the risk of post-mononucleosis
lymphoproliferation, thiopurine treatment should be avoided
in young (b35 years) men seronegative for EBV. In this line,
systematic EBV serology before initiating immunosuppressants
should be discussed, even though this measure is not
recommended in the current ECCO guidelines.261.6. Treatment and Prognosis of IBD-related LD
Besides stopping immunosuppressants, which may result in
some cases in LD regression,27 there is no specificity in the
treatment of LD in IBD patients. There is no specificity in the
prognosis of LD in IBD patients.1.7. Key-messages- Thiopurine-treated IBD patients have a three- to fivefold
increased risk of developing LD. This risk increases with age
and disease duration.
- Adding anti-TNF therapy to thiopurines treatment do not
significantly increase the risk of LD compared to patients treated
by thiopurines alone
- Determination of systemic EBV viral load should be performed in
case of clinical suspicion of LD in IBD
- Avoiding thiopurines (preferring other immunosuppressants)
should be considered in EBV-negative young males
- Avoiding to prolong combo-therapy of anti-TNF therapy and
thiopurines beyond two years in young men with controlled IBD
could limit the risk of HSTCL1.8. Areas for Future Research- The risk of LD associated with anti-TNF monotherapy in IBD
should be identified. A large European-wide prospective safety
cohort is needed.
- In parallel, we should work at identifying markers of
“prelymphoma state” in order to be able to prevent, and if not
possible, to detect early IBD-related LD2. Uterine Cervix Abnormalities
Cervical cancer is the second most common cancer in
women world-wide,28 and the incidence of cervical cancer
is higher in developing countries than in developed
countries that developed an effective cervical screening
program.29,2.1. Epidemiology in the General Population
The worldwide prevalence of human papillomavirus (HPV)
infection in women is about 10%. High-risk HPV is now
considered to be the causal agent of almost all cases of
invasive cervical cancer and cervical intra-epithelial neo-
plasia (CIN). HPV has been identified as the ‘necessary
cause’ of cervical cancer. In other words, cancer does not
develop in the absence of persistent HPV DNA .30 More than
95% of cervical cancer biopsies contain HPV genomes.31 The
development of cervical cancer subsequent to HPV infection
is not unavoidable. Seventy percent (70%) of women
experience a viral clearance within 12 months after infec-
tion (91% within 24 months), leading to frequent spontane-
ous resolution of early dysplastic changes.32 It has been
estimated that among one million women who become
infected, only 10% (100,000) will develop pre-cancerous
cervical cell changes. Among these, approximately 8%
(8,000) will develop early cancer (carcinoma in situ) and
approximately 1600 of these women will develop invasive
cervical cancer.33. HPV infection is the most common
sexually transmitted infection and the infected women
become asymptomatic carriers. HPV transmission may
occur with skin-to-skin genital contact. More than 40
subtypes of HPV have been identified, of which at least 15
are known to be oncogenic. According to the potential
oncogenic effect, HPV genotypes are classified into two
groups: high-risk (or oncogenic) types and low-risk types.34,,
HPV types 16, 18, 45 and 31 are the most ongogenic types,35
while HPV-6 and 11 cause benign warts and lesions that do
not become malignant.36 Types 16 and 18 together are the
causative agent of more than 50% of cervical pre-cancerous
lesions (high-grade dysplasia), as well as more than 70% of all
cases of cervical squamous cell carcinoma and adenocarci-
noma, and 25% of low-grade cervical lesions.332.2. Carcinogenesis
Human papillomavirus (HPV) is a double-stranded DNA virus
that is non-enveloped and has an icosahedral capsid. It has
been shown that viral oncoprotein E6 is involved in
the transformation of host cells. Malignant cells show
deregulated overexpression of E6 and E7 oncoproteins,
which ultimately leads to the development of cancer.37 The
inactivation of p53 compromises the integrity of the
replicated DNA and causes DNA damage and chromosomal
instability. These abnormalities result in cell proliferation
or tumor development. HPV E6 proteins are also capable of
immortalizing the host cell by preventing the shortening
of telomere length, and thereby immortalizing the host
cell.
36 F. Magro et al.2.3. Risk Factors for Uterine Cervix Abnormalities in
the General Population
Several risk factors have been associated with the develop-
ment of cervical cancer, namely prolonged combination oral
contraceptive use, number of sexual partners, parity, early
age at first intercourse (before the age of 20 years), tobacco
smoking, co-infection with other sexually transmitted agents,
concomitant infection with multiple HPV types, HPV viral
load, low social class, and multiplicity of sexual partners.
Increasing parity is directly related to an increased risk for
developing cervical cancer. Women with one/two or seven
prior full-term pregnancies have a two-fold and four-fold
increased risk compared with nulliparas, respectively. The
strong confounding effects from the lifestyle behavioural
factors must be taken into account, while interpreting the
data on oral contraceptive use. Similarly, it now seems that
the increased risk (if any) of cervical cancer among smokers
seems to be attributed to the increased acquisition of
high-risk HPV infections, of which the smoking status is an
independent predictor in a multivariate model.
In IBD current smokers,38,39 women aged of less than
20 years at diagnosis,40 extensive disease,40 exposure to 10
or more prescriptions of oral contraceptives,41 and oral
contraceptives39 were found as risk factors for cervical
dysplasia. However, in most of these studies, important HPV
risk factors were not evaluated, such as the number of
sexual partners, sexual transmitted diseases and education
level.40,38,39,41,42
2.4. Data From other Immune Related Diseases than
IBD
Previous studies have demonstrated an increased prevalence
of atypical cervical smears in patients with systemic lupus
erythematosus. In a meta-analysis, the OR was 4.43 In some
studies, the risk of cervical neoplasia was higher in those
women exposed to cyclosphosphamide.44.Patients using this
drug developed cervical dysplasia in a shorter time.45 A
direct relationship between the cumulative dose of cyclo-
phosphamide and the risk of cervical dysplasia was also
identified.46 In women with rheumatoid arthritis, an
increased prevalence of abnormal cervical cytology was
found compared with a control population. However, this
may be related to chronic inflammatory disease and sexual
behavior, because women with rheumatoid without abnor-
mal cervicovaginal cytology have less sexual partners than
those with rheumatoid arthritis and abnormal cytology.47
Cervical cancer accounts for 3% of post-transplant
malignancies and is reported to be the commonest form of
neoplasia, after skin cancer, in female transplant recipi-
ents.48, In the study by Courtney et al.,49 in 173 women
submitted to renal transplantation, the incidence of smear
test abnormalities was 20% in renal transplant recipients
compared with 7% in the general population. In contrast, in
two recent cohorts50,51 it was suggested that transplant
recipients receiving long-term immunosuppression are not at
increased risk of HPV infection and CIN than healthy
controls. HIV-positive women are also at increased risk of
developing dysplasia and invasive carcinoma of the uterine
cervix.522.5. Risk Factors of Uterine Cervix Abnormalities in
IBD
One of the first reports on the links between immunosup-
pressant use in IBD and cervical cancer comes from Connell
et al. in 1994.53 Two cases of invasive cervical cancers among
366 women exposed to azathioprine (0.5 expected, P =0.090)
were reported. More recently, two population-based studies,
one from North of California, and the other from Manitoba,
were published. The former 38, retrospective, showed an
adjusted odds ratio (OR) of 1.45 for risk of cervical cancer in
IBD patients. Odds ratios associated with drug use were 1.65
for 5-aminosalicylates, 2.79 for corticosteroids, and 3.45 for
immunodulators (all P b 0.05). The latter study was a case–
control study nested in a population-based cohort.41 There
was no association between cervical abnormalities and
ulcerative colitis. The increase in risk in women with Crohn’s
disease was limited to those exposed to 10 or more pre-
scriptions of oral contraceptives. The combined exposure to
corticosteroids and immunosuppressants was associated with
an increased risk of cervical abnormalities. There was no
interaction between the effect of IBD and corticosteroids
and/or immunosuppressants.
In a retrospective study from a tertiary care center in
Scotland,40 362 women with IBD were compared with 1644
controls from the community. There was no difference in the
proportion of abnormal smears between women with IBD and
matched controls. There was no association with exposure to
any immunosuppressant specifically, even when limited to
women who were on drug at the time of smear. Bhatia et al. 42
in a tertiary center conducted a retrospective case–control
study with 116 women with IBD and a similar number of
controls. Eighteen percent of IBD patients and 5% of controls
had an abnormal Papanicolaou (Pap) smear (p = 0.004).
There was no association with the use of immunosuppressive
medications. Kane et al. 39 reported the comparison
between 40 IBD patients and 120 controls. The incidence
of any abnormal Pap smear and higher-grade lesions was
statistically higher in the IBD group versus controls.
Patients on an immunosuppressant were significantly
more at risk than controls and non-exposed IBD patients.
Finally, two retrospective studies published as abstracts
suggested higher HPV prevalence in IBD patients on
immunosuppressants and an increased risk of Pap smear
abnormalities in patients exposed to immunosuppressants
and smokers. Taking into account these conflicting data, no
definite conclusion on the role of exposure to immunosup-
pressants on the risk of cervical cancer in IBD patients can
be made at the moment. In addition, we have few data on
sexual activity and frequency of cervical screening in the
IBD population, with or without immunosuppressants. It
was reported that only 20% of women with IBD report
moderate to high sexual activity and it is known that sexual
activity and the number of partners have an impact on the
rate of cervical dysplasia. 54 Immunosuppressants were
found independent predictors of lower use of Pap testing in
IBD.55,56 The prevalence of surveillance in the different
studies was small and varied from 11 to 65%.40,41,38,39,42 Of
note, in the two studies that demonstrated an impact of
immunosuppressant use on the risk of cervical lesions, the
number of IBD patients taken these drugs was lower than
60. 39,42
37ECCO workshop-Extra-intestinal cancers2.6. Screening and PreventionPapanicolaou (Pap) test is the reference screening test for
cervical alterations, with a sensitivity ranging from 30% to
87% and a specificity ranging from 86% to 100%.57 Among
women with IBD, differences in screening rate between
women with and without exposure to immunosuppressants,
according to age, socioeconomic status, prior diagnostic
testing, and intensity of healthcare utilization, were tested
by multivariate analysis.56 Older age, lower socioeconomic
status, lower intensity of healthcare utilization, Crohn's
disease, and exposure to immunosuppressants were inde-
pendent predictors of lower use of Pap testing. Gastroen-
terologists should strengthen recommendations of routine
Pap smears in women with IBD patients, since Long et al.
reported that only 70% of women with IBD received cervical
testing at least once every 3 years.55 Risk factors for
suboptimal screening included Medicaid insurance, immuno-
suppressant medication use, and increased age. Cytological
screening at the population level every 3–5 years results in a
substantial reduction (up-to-80%) in the incidence of
cervical cancer.58 Reduction in incidence of grade 3 cervical
intraepithelial neoplasia (CIN3) is a surrogate indicator of
effectiveness. Cervical cytology is the currently recom-
mended standard test for cervix screening, which should
start in the age range of 20–30 years,59 but preferentially
not before the age of 25–30 years, depending on the burden
of the disease in the population and the available re-
sources.60 It is recommended to continue screening at 3- to
5-year intervals until the age of 60 or 65.58 Stopping
screening in older women is probably appropriate among
women who have had three or more consecutive previous
(recent) normal cytology results. Women under 30 years of
age should not be screened for HPV, due to the high rate of
viral clearance.58.Young women who are infected with HIV
and/or are immunocompromised should obtain a Pap test
twice in the first year after diagnosis of HIV infection and, if
the results are normal, annually thereafter.61
The current HPV vaccines are tetravalent HPV4 and
bivalent HPV2 and both provide protection against the most
two prevalent oncogenic HPV genotypes, namely HPV 16 and
18, which account for about 70% of cervical cancers. HPV4 is
directed against HPV types 6, 11, 16, and 18, and was licensed
by the Food and Drug Administration (FDA) for use in females
in June 2006. Bivalent HPV vaccine (HPV2; Cervarix,
GlaxoSmithKline) is directed against HPV 16 and 18, and was
licensed for use in females in October 2009. Both vaccines are
not live vaccines. Therefore, these vaccines can be safely
administered to persons who are immunocompromised as a
result of infection (including HIV), disease, or medications.
The immune response and vaccine efficacy might be less than
that in immunocompetent persons. For immunocompromised
males, ACIP (Advisory Committee on Immunization Practices)
recommends routine vaccination as for all females, and
vaccination through age 26 years for those who have not
been vaccinated previously or who have not completed the
3-dose series. ACIP recommends routine vaccination of
females aged 11–12 years. Vaccination is also recommended
for females aged 13–26 years who have not been previously
vaccinated or who have not completed the full series. Ideally,
vaccine should be administered in sexually naïve individuals,
before potential genital exposure to HPV. However, females
who might have already been exposed to HPV should bevaccinated. Sexually active females who have not been
infected with any of the HPV vaccine types would receive
full benefit from vaccination. It seems that vaccination
provides less benefit to females who have already been
infected with one or more of the four vaccine HPV types. Pap
testing and screening for HPV DNA or HPV antibody are not
needed before vaccination at any age (http://www.cdc.gov/
mmwr/preview/mmwrhtml/rr5602a1.htm).
2.7. Key-messages
- The majority of the studies do not demonstrate an association
between uterine cervical cancer and IBD.
- It is not clear whether immunosuppressants are associated with
an increased risk of cervical dysplasia in IBD, while in some other
immunomediated diseases, exposure to immunosuppressants is
associated with higher dysplasia prevalence.
- Smoking cessation and counseling about family planning
(avoiding long term use of combination oral contraceptive) and
sexual practices should be adopted as preventive proceedings in
IBD women with cervix abnormalities.
- Gastroenterologists need to improve the rate of recommending
routine Pap smears in women with IBD.
- Young immunocompromised women should obtain a Pap test
twice in the first year after diagnosis and, if the results are
normal, annually thereafter
- Human papillomavirus (HPV) vaccine should be implemented in
all women between 9 and 26 years prior initiation sexual activity
2.8. Areas for Future Research
- Specifically designed epidemiological studies are needed for
determining whether IBD women exposed to immunosuppresants
are at increased risk for HPV infection, persistent HPV infection,
abnormal cervical cytologies, uterine cervical dysplasia, cervical
cancer and adverse outcome of cervical cancer.
- In patients with chronic inflammatory diseases, epidemiological
and mechanistic studies should precise the individual roles of the
type of disease, genetically-driven susceptibility and the type,
dosage and duration of immunosuppressants.
3. Skin Cancers
3.1. Introduction
Skin cancers are a real public health problem, with increasing
incidence throughout the world.62,63 Non-melanoma skin
cancer (NMSC) is the most common human cancer.64 Melano-
mas are much less frequent than NMSC, but the incidence of
melanomas continues to increase worldwide.65. Diagnosis is
made clinically and confirmed by histology. Surgical excision is
the standard of care for the majority of cases, although
multiple non-invasive treatments are validated for NMSC.
Previous experience from transplant recipients indicates that
exposure to thiopurines is associated with an increased risk of
NMSC.66 A recent meta-analysis showed that anti-TNF treat-
ment increases the risk of NMSC, and possibly that of
melanoma among patients with rheumatoid arthritis.67
Recent evidence in IBD indicates that ongoing and past
exposure to thiopurines significantly increases the risk of
NMSC in patients with IBD.68 The risk of melanoma in
patients who receive thiopurines for IBD is not increased
whereas this risk is increased by the use of biologics.69 Here
38 F. Magro et al.we demonstrate that IBD patients on immunosuppressants
should be protected against UV radiation and receive
lifelong dermatologic screening.
3.2. Epidemiology and Risk Factors
3.2.1. General Population
Skin cancers encompass cutaneous melanomas and NMSC.
Most of NMSC diagnosed are basal cell carcinomas (BCC) and
squamous cell carcinomas (SCC). The remaining cases of
NMSC include cutaneous lymphomas, adnexal tumours,
Merkel cell carcinoma, and other rare primary cutaneous
neoplasms.
3.2.1.1. Epidemiology and Risk Factors of Cutaneous
Melanoma. Since the mid 1960s, melanoma incidence has
risen by 3–8% per year in most people of European
background.70 For men, incidence of melanoma varies
between 9.7 per 100,000 per year in the UK71 and 41.4 per
100,000 per year in Australia.72 In countries with high
incidence rates, men have more melanomas than women,
in contrast to countries with lower incidence rates.73
Caucasians and elderly people have also higher rates of
melanoma.70,74 Risk factors for melanoma include a combi-
nation of constitutional predisposition: strong family history,
multiple benign nevi (N 100) and/or multiple atypical nevi,
previous melanoma, previous NMSC, immunosuppression
(transplant recipients75 or patients with AIDS76), sun sensi-
tivity (Fitzpatrick type I skin, freckling, blue eyes, red hair),
and exposure to environmental factors (UV exposure) and
particularly blistering sunburns in early life.
3.2.1.2. Epidemiology and Risk Factors of NMSC. NMSC are
the most common human cancers,64 and the incidence of
BCC is increasing by 10% per year worldwide. In the US, NMSC
constitute more than one-third of all cancers with over one
million new cases per year, of which roughly 20–30% are of
SCC. The standardized ratio of BCC to SCC is roughly 4:1.77
The incidence of BCC for men is approximately 128, 175 and
2,055 per 100,000 person-years in Europe78, the US79 and
Australia,80 respectively. These figures are 105, 124 and
1,195 for women. The incidence of SCC for men is
approximately 25, 155 and 1332 per 100,000 person-years
in Europe,78 the US79 and Australia,80 respectively. These
figures are 9, 71 and 755 for women.
3.2.1.2.1. Genotypic Risk Factors. Many syndromes
predispose to cutaneous SCC, such as xeroderma pig-
mentosum, albinism, etc. Muir-Torre syndrome,.In addition,
several genodermatoses are associated with the development
of BCC.
3.2.1.2.2. Phenotypic Factors. Men are at higher risk of
NMSC than women and they have a body site-specific
incidence (lip [particularly lower lip], orbit, naso-labial
area, ear, nose, cheek) compared to the dorsum and the
hands, which are equally affected in both sexes.80 Incidence
of NMSC increases with age, and 80% of cases occur in people
aged 60 years and older.81 White populations have an
increased risk of NMSC, especially those with blue eyes,
fair complexion, skin type I and II and red or blond hair.82 For
SCC, there are precursor lesions, including actinic keratoses,83Bowen’s disease, chronic ulcers or burn scars, but there are no
precursor lesions for BCC.64
3.2.1.2.3. Environmental Factors. Solar UV radiation is
the most important risk factor for both SCC and BCC,84 but
the effect on risk of SCC is higher than on BCC.85 Cumulative
lifetime sun exposure is strongly associatedwith SCC, although
intermittent intense sun exposure and exposure during
childhood are risk factors for BCC.86 Exposure to UVB radiation
is a specific risk factor for BCC87. The use of tanning beds,
particularly amongst young women, has been associated with
a statistically significant increased risk of development of BCC
(both in high school / college age and age 25–35), as well
increased risk of SCC in age 25–35 year-old women.88 The
rising incidence rate of NMSC is probably due to a combination
of increased sun exposure (and use of tanning beds), increased
outdoor activities, changes in clothing style, increased
longevity and ozone depletion.64
Infection by β HPV (without specific subtypes) is
associated with SCC among immunocompetent and
immunosuppressed patients,89 but the association between
HPV and BCC is not clearly established.90 HPV facilitates
UV-related carcinogenesis by preventing apoptosis and
impairing DNA repair.91 The risk of SCC increases
65-250-fold and risk of BCC increases 10–16-fold in white
transplant recipients, with an inversion of ratio of BCC to
SCC, because SCC occurs more frequently in transplant
recipients than do BCC.92 Other risk factors are HIV
infection, non-Hodgkin lymphomas, especially chronic lym-
phocytic leukaemias, PUVA-therapy, use of photosensitizing
drugs (eg. fluoroquinolones), occupational factors such as
exposition to industrial products (eg. polycyclic hydrocar-
bons from coal tar products, arsenic), oonizing radiation
(mainly for BCC), and tobacco smoking (mainly for SCC).
3.2.2. Epidemiology in IBD Patients
Long et al., found an incidence rate ratio of NMSC of 1.64
(95% confidence interval [CI] = 1.51–1.78) among IBD pa-
tients compared to controls.93 Singh et al. showed an
increased risk for BCC, compared with controls, with an
hazard ratio [HR] of 1.20 (95% CI = 1.03–1.40).94 There was
an increased risk of NMSC among Crohn's disease (CD)
patients, with a standardized incidence ratio (SIR) of 1.95
(95% CI = 1.50–2.50), whereas this was not statically
significant for melanoma, (SIR 1.23 (95% CI = 0.94-1.58).95
In the CESAME cohort study, an excess of NMSC was observed
in the overall IBD population (SIR, 2.89; 95% CI =
1.98-4.08),68 while the risk of melanoma among the overall
IBD population was similar to that observed in the general
population (SIR, 0.64; 95% CI = 0.17–1.63).96
IBD patients are likely to have the same risk factors than
general population, but in addition have treatment-specific
risks. The increased risk of NMSC in IBD patients who receive
thiopurines is now well-documented, with HR of 5.9 (95%
CI = 2.1–16.4; p = .0006) for ongoing treatment and 3.9
(95% CI = 1.3–12.1; p = .02) for past exposure in the CESAME
cohort study.10 Consistently, Long et al. found that recent
thiopurine use (≤90 days) and persistent thiopurine use
(N365 days) were associated with NMSC, with adjusted odds
ratio [OR] of 3.56 (95% CI = 2.81–4.50) and 4.27 (95% CI =
3.08–5.92), respectively.93 For Setshedi et al., a diagnosis of
NMSC was significantly associated with thiopurine exposure
in IBD patients (odds ratio 5.0, 95% IC = 1.1–22.8). For Singh
39ECCO workshop-Extra-intestinal cancerset al., use of thiopurines in IBD patients also increased the
risk of SCC (HR 5.40; 95% CI = 2.00–14.56), compared with
controls.94.
The use of methotrexate or calcineurin inhibitors (tacro-
limus or cyclosporine) was not significally associated with
NMSC in IBD patients.93 For biologics (adalimumab or
infliximab), there is an increased risk of NMSC in CD patients,
with an adjusted OR of 2.07 (95% CI = 1.28–3.33) and 2.18
(95% CI = 1.07–4.46) for recent use (≤90 days) and persis-
tent use (N365 days), respectively.93
Combinations of immunosuppressants and biologics were
associated with NMSC risk in CD patients, with an adjusted
OR of 5.85 (95% CI = 3.2–10.8; p b 0.001) and 6.75 (95% CI =
2.74–16.65; p b 0.001) for recent use (≤90 days) and
persistent use (N365 days), respectively.93 In the CESAME
cohort study, the risk of melanoma was not increased in IBD
patients previously treated with thiopurines (SIR, 0; 95%
CI = 0–3.11).96 In a recent study, the risk of melanoma was
increased in IBD patients with biologics (OR, 1.88; 95% CI =
1.08–3.29).69
The impact of IBD-related medications on skin cancer risk
among IBD patients is summarized in Table 2.3.3. Carcinogenesis
3.3.1. Cutaneous Melanoma
UV radiation has direct mutagenic effects on DNA, by
stimulating the cellular constituents of the skin to produce
growth factors, by reducing cutaneous immune defenses,
and by promoting reactive oxygen species of melanin that
cause DNA damage and suppress apoptosis.97. Main molec-
ular pathways are shown in Fig. 1.3.3.2. Non-melanoma Skin Cancer
Similar to melanoma, UVB radiation causes direct damage
to DNA and RNA, leading to generation of mutagenic
photoproducts98. UVA radiation is less mutagenic and causes
indirect DNA damage.99 Main molecular pathways are shown
in Fig. 2.
For thiopurines, mechanisms which may predispose to
skin cancers are now better understood. Azathioprine causes
the accumulation of 6-thioguanine (6-TG) in patients' DNA.
Under the action of ultraviolet A (UVA), there is a production
of reactive oxygen species (ROS). ROS lead to DNA mutations
and oxidative stress, linked to oncogenesis. AzathioprineTable 2 Impact of medications on skin cancer risk among
inflammatory bowel disease patients.
NMSC Melanoma
Thiopurines + −
Methotrexate − −
Calcineurin inhibitor a − −
Biologic b + (CD) +
Combination therapy + (CD) ?
NMSC, non-melanoma skin cancers; CD, Crohn’s disease.
a Tacrolimus or cyclosporine.
b Infliximab or adalimumab.could also generate non sun-exposed BCC by causing
mutations in PTCH, a candidate tumor suppressor gene89.
Mechanisms at the origin of the increased risk of skin
cancer with biologics remain unclear. Indeed TNF-alpha
produces a variety of cellular responses which, with sustained
increased levels of activity, could either facilitate or inhibit
tumorgenesis.1003.4. Clinical Presentation and Diagnosis
Patients often point out moles or other skin lesions that are
itching, tender, scaly, oozing, bleeding, red, swollen, and/or
non-healing. While many skin lesions with these features are
non-malignant, these cutaneous symptoms and signs may be
indicative of a premalignant or malignant lesion. NMSC,
including BCC, SCC, and variants, are the most common form
of cancer diagnosed in humans. While varying by country,
ethnicity, and gender, approximately 1 in 3 Americans will
develop NMSC in their lifetime, usually after the 5th decade.64
However, NMSC may appear in all age groups, particularly in
younger individuals with chronic immunosuppression.
BCC comprise the majority of skin cancers. BCC present
with a variety of clinical and histological morphologies. BCC
can appear as a firm pearly white, translucent, or waxy
nodule, often with visible blood vessels, and occasionally
with crusting or an ulcerated center. They commonly have a
characteristic rolled border (Fig. 3A). BCC can also appear as
flat, scaly, flesh-colored, red, or brown plaques (Fig. 3B).
Less common variants can appear pigmented, scar-like, or
cystic. Approximately 80% of BCC arise on the head and
neck, 15% on the trunk, and less than 5% on the extremities
and groin.101 BCC on the face often arise on the temples,
forehead, and nose and may bleed easily with minor trauma.
Other common locations include the scalp and posterior neck
in men. BCC can arise on the upper back and chest in both
genders.
SCC, while less common than BCC in the general
population, are significantly increased in incidence in
chronically immunosuppressed populations (65-fold in trans-
plant recipients)102 and are more common than BCC in
individuals with darker pigmentation. SCC often appear as a
firm red nodule, a scaly growth that crusts or bleeds, or a
non-healing sore (Fig. 3C and D). An indurated component
may be appreciated on palpation. SCC development favors
sun-exposed areas, including the nose, forehead, lower lip,
ears, dorsal hands and forearms. Less common sites include
chronic ulcers, chronic fistulas, burns, or sites of prior
radiation exposure. SCC in situ (Bowen’s disease) presents as
scaly red papules or plaques, often with crusting. Bowen’s
disease can arise in sun-exposed areas and has also been
associated with HPV infection of the genitals.
Melanoma, while much less common than NMSC, pos-
sesses risk for far greater morbidity and mortality. Most
melanomas present as irregularly-bordered plaques and
nodules that possess a wide range uneven pigmentation
(Fig. 3E and F). Occasionally, melanomas can present
without pigmentation or can have uniform coloration. They
tend to grow and evolve over time. While melanomas often
present in sun-exposed areas, several sub-types are more
commonly found in sun-protected sites and even on mucosal
surfaces.
UV solar radiation
Apoptosis inhibitors
(Bcl-2 and Bcl-xL) MELANOMA
Growth factors
MCR1 variants
Ras/RAF
pheomelanin
NRAS/BRAF 
mutations
CDKN2A 
mutations
p14ARF 
mutations
p53 degradation
Figure 1 Overview of the pathogenesis of melanoma. Bcl, B-cell lymphoma derived protein; MCR1, melanocortin-1 receptor; NRAS,
neuroblastoma RAS viral (v-ras) oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CDKN2A, cyclin-dependent
kinase inhibitor 2A; p14ARF, 4000 MW alternate reading frame protein.
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Patients with sustained immunosuppression are at increased
risk of NMSC (and less commonly melanoma),102 but
additional factors can affect the risk in particular individ-
uals. Fair skin, atypical moles, advanced age, a history of
painful or severe sunburns, outdoor occupation, and a family
history of skin cancer add to skin cancer risk. A personal
history of skin cancer also adds to the risk, as the 3-year
cumulative risk of developing another NMSC is around
47%.103
IBD patients on immunosuppressant therapy should be
screened annually in a room with good lighting and while
disrobed but covered modestly with a gown, which can be
moved as appropriate to examine different body regions.
Skin cancer screening can be done by a primary care
physician, the gastroenterologist, or a dermatologist. IfUV solar rad
PTCH1 
mutations
MCR1 gene
variants
Tumor suppresor
genes (TP53, CDKN1A, …) 
inactivation
NON-MELA
SKIN CAN
Figure 2 Overview of the pathogenesis of non-melanoma skin canc
TP53: tumor protein 53; CDKN1A: cyclin-dependent kinase inhibitor 1A
glutathione S-transferase theta 1; CYP2D6: cytochrome P450, family 2possible, it is recommended that patients perform “self-skin
exams” in their homes at least every 2–3 months.
It is especially important to screen “hidden areas” that an
individual patient might not readily see, including the scalp,
the back, between the fingers and toes, the backs of the legs
and the lower legs, the groin, and the soles of the feet. It
can be helpful to take photos of any moles as a baseline for
comparison to determine whether evolution of lesions is
taking place.
Skin lesions, particularly those of a pigmented nature,
should be evaluated with the ABCDE criteria: A, Asymmetry
increases the risk of malignancy; B, irregular Borders increase
the risk of malignancy; C, multiple Colors in one lesion
increases the risk of malignancy; D, a Diameter greater than
6 mm increases the risk of malignancy; E, Evolution of a lesion
over time increases the risk of malignancy. Skin lesions
fulfilling any of the ABCDE criteria as well as any lesion that isiation
XPC mutations
GSTT1 / CYP2D6 
polymorphisms 
Telomerase 
reactivation
NOMA
CER
ers. PTCH1: patched homolog 1; MCR1: melanocortin 1 receptor;
; XPC: xeroderma pigmentosum complementation group C; GSTT1:
, subfamily D, polypeptide 6.
A B C
D E F
Figure 3 A, nodular basal cell carcinoma on the right temple of a 78 year-old woman; B, large superficial basal cell carcinoma on
the left upper back of an 82 year-old man; C, ulcerated squamous cell carcinoma on the right cheek of a 73 year-old man; D, crusted
and ulcerated squamous cell carcinoma on the forearm of an immunosuppressed 62 year-old man; E, characteristic irregular
pigmentation pattern and shape of a melanoma in situ of the forearm; F, darkly pigmented nodules and erosion of an invasive
melanoma on the forearm.
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to the patient or the practitioner should be biopsied for
histopathological diagnosis. Obtaining tissue adequate for
diagnosis and with a margin of healthy tissue surrounding (if
possible based on size and location) allows for more accurate
diagnosis. If the need for biopsy is uncertain or performing the
biopsy would be challenging given the location or patient’s
circumstance, referral should be made to a dermatologist as
appropriate.3.6. Treatment and Prognosis
BCC are rarely invasive and can generally be treated with
simple local resection. The survival rate in the absence of
metastasis is nearly 100%. Superficial BCC can be successfully
treated with topical therapies (including imiquimod or
5-fluorouracil cream), liquid nitrogen cryotherapy, photody-
namic therapy, or electrodessication and curettage. Neg-
lected BCC can lead to significant local tissue destruction, but
timely treatment generally removes BCC completely. Com-
plicated tumors, including those in high-risk areas or
cosmetically sensitive areas (around the nose, eyes, mouth,
ears, or associated with the nail unit), recurrent tumors,
those with indistinct borders, aggressive histological sub-
types, or those in radiation fields should be treated with Mohs
micrographic surgery. Resection is quite effective, with same
site recurrence rate of 5-10% for standard excision and less
than 1% at 5 years for Mohs micrographic surgery104. For those
lesions who are not candidates for surgery, radiation therapy
can be considered. Cure rates for non-surgical modalities are
somewhat lower, but still considered effective in low risk
individuals. Individuals with high-risk tumors or comorbidities
have somewhat higher rates of recurrence.SCC has a similar rate of successful resection as BCC in
non-complicated situations, and has a 5-year survival rate
N90% with timely and complete resection.
Approximately 2–6% will present with nodal or distant
metastasis. For patients with lymph node metastases of the
head and neck, the 5 year survival rate has recently been
shown to be 44%.77 Immunosuppressed patients who develop
SCC tend to develop more numerous and more aggressive
tumors, particularly with increased duration of immunosup-
pression, composition of the immunosuppressive regimen
(particularly thiopurines), and advanced age.102 These
individuals have a worse prognosis. Other predictors of
poor outcome in SCC include a diameter N2 cm, a depth
N2 mm, recurrence at the same site, and perineural
invasion. While many IBD patients with SCC can be treated
with modalities similar to those used for BCC (including
standard excision and radiation therapy), those with
high-risk lesions (including the predictors of poor outcome
above) as well as locations including the lips, ears, hands,
feet, and genitals, require prompt and aggressive manage-
ment with Mohs micrographic surgery and evaluation for and
management of nodal disease, where appropriate.
Due to potential mortality and morbidity, melanoma
requires wide local resection, and recommendations for
resection margin increase with the depth of the melanoma.
Sentinel lymph-node biopsy is recommended based on the
clinical stage of the lesion, but can cause marked morbidity,
and effect on overall mortality remains unclear. Until
recently, the only FDA-approved adjuvant therapy for
melanoma was high-dose interferon alfa-2b, for high-risk
resected melanoma. Recently, both vemurafenib (a B-Raf
inhibitor for use in individuals possessing a BRAF gene
mutation) and ipilimumab (a fully human monoclonal anti-
body that promotes cytotoxic destruction of melanoma cells)
42 F. Magro et al.have been FDA-approved for individuals with late-stage
melanoma. The most important prognostic factor in melano-
ma is the histological depth (Breslow depth) of the primary
tumor. Prognosis worsens with increasing tumor depth, the
presence of histological ulceration, and lymph node
involvement.
There is a high rate of development of skin cancer in
immunosuppressed IBD patients, and also a high rate of
development of a second cutaneous malignancy in individ-
uals with a history of NMSC. There is also a lower, but still
elevated rate of developing a second melanoma, particularly
in those who are immunosuppressed, making regular
monitoring and skin exams essential in IBD patients who
have been immunosuppressed.
3.7. Key-messages
- IBD patients are at increased risk of developing NMSC
- Thiopurines increase the risk of NMSC among IBD patients whereas
biologics are associated with an increased risk of melanoma.
- Methotrexate and calcineurin inhibitors do not seem to be
associated with an increased risk of skin cancer in IBD
- A regular dermatological screening and protection against UV
radiation are recommended lifelong for all IBD patients receiving
immunosuppressive therapy.
3.8. Areas for Future Research
- Whether IBD patients are at increased risk of having melanoma
awaits confirmation, and the effects of combination therapy and
methotrexate on skin cancer require further investigation.
- The impact of a regular dermatological screening and protection
against UV radiation on skin cancer risk, as well as prognosis of
such malignancies among IBD patients, need to be evaluated in
large prospective studies.
- Recurrence rates of skin cancer among IBD patients are unknown.
Anecdotal reports suggest that a minority of patients with prior
NMSC will experience accelerated development of new NMSCs after
initiation of anti-TNF therapy. Large prospective cohort studies are
needed to elucidate the frequency and severity of this risk.
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